Baudax Bio, Inc.
DelistedCIK 1780097fmd_0ZWR8TBTZES4J9TJ0D0H38N49MManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2023, 23 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 1 | 1 |
| Cost of revenue | – | – | 2 | 2 | 7 |
| Gross profit | – | – | (1) | (1) | (6) |
| Research and development | 36 | 20 | 9 | 3 | 3 |
| Selling, general and administrative | – | 27 | 43 | 23 | 15 |
| Total operating expenses | 74 | 33 | – | – | – |
| Operating income | (74) | (33) | (75) | (26) | (18) |
| Interest expense | – | – | 1 | 2 | – |
| Other non-operating income (expense) | (0) | (0) | 0 | (1) | (2) |
| Income before taxes | (74) | (33) | (76) | (26) | (20) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (74) | (33) | (76) | (26) | (20) |
| Net income | (74) | (33) | (76) | (20) | (59) |
| Net income to common shareholders | – | – | (76) | (22) | – |